CABALETTA BIO, INC. (CABA): Price and Financial Metrics


CABALETTA BIO, INC. (CABA)

Today's Latest Price: $11.59 USD

0.04 (0.35%)

Updated Oct 22 4:00pm

Add CABA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

CABA Stock Price Chart Interactive Chart >

Price chart for CABA

CABA Price/Volume Stats

Current price $11.59 52-week high $19.63
Prev. close $11.55 52-week low $5.51
Day low $11.15 Volume 46,600
Day high $11.73 Avg. volume 105,618
50-day MA $11.05 Dividend yield N/A
200-day MA $10.86 Market Cap 278.62M

CABALETTA BIO, INC. (CABA) Company Bio


Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.


CABA Latest News Stream


Event/Time News Detail
Loading, please wait...

CABA Latest Social Stream


Loading social stream, please wait...

View Full CABA Social Stream

Latest CABA News From Around the Web

Below are the latest news stories about Cabaletta Bio Inc that investors may wish to consider to help them evaluate CABA as an investment opportunity.

Cabaletta Bio to Present at Multiple August Investor Conferences

PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and…

GlobeNewswire | August 3, 2020

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | July 24, 2020

Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies

Cabaletta Bio, Inc. (CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, and Artisan Bio, Inc., a precision cell therapy engineering company, today announced they have signed a research and collaboration agreement to accelerate development of next-generation CAAR T cell therapies for patients with B cell-mediated autoimmune diseases. “This collaboration agreement with Artisan provides Cabaletta Labs with the potential to integrate this advanced gene editing and engineering technology into our next-generation CAAR T products as we continue to expand and enhance our CABA platform,” said Gwendolyn Binder, Ph.D., EVP Science and Technology at Cabaletta Bio.

Yahoo | July 7, 2020

Hedge Funds Keep Buying Cabaletta Bio, Inc. (CABA)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | June 24, 2020

Cabaletta Bio, Inc. (CABA) Moves to Strong Buy: Rationale Behind the Upgrade

Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research | June 1, 2020

Read More 'CABA' Stories Here

CABA Price Returns

1-mo 18.87%
3-mo -6.08%
6-mo 81.38%
1-year N/A
3-year N/A
5-year N/A
YTD -17.04%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.791 seconds.